ID   CCRF-CEM/MTX140-LV
AC   CVCL_5H83
SY   CEM/MTX140LV
DR   cancercelllines; CVCL_5H83
DR   Wikidata; Q54809029
RX   PubMed=9369939;
RX   PubMed=12482398;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX).
CC   Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
CC   Cell type: T-cell; CL=CL_0000084.
DI   NCIt; C7953; Childhood T acute lymphoblastic leukemia
DI   ORDO; Orphanet_99861; Precursor T-cell acute lymphoblastic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0207 ! CCRF-CEM
SX   Female
AG   3Y11M
CA   Cancer cell line
DT   Created: 14-12-15; Last updated: 05-10-23; Version: 16
//
RX   PubMed=9369939; DOI=10.1111/j.1349-7006.1997.tb00467.x;
RA   Miyachi H., Takemura Y., Kobayashi H., Ando Y.;
RT   "Cytotoxicity of trimetrexate against antifolate-resistant human
RT   T-cell leukemia cell lines developed in oxidized or reduced folate.";
RL   Jpn. J. Cancer Res. 88:900-906(1997).
//
RX   PubMed=12482398; DOI=10.1006/bcmd.2002.0530;
RA   Efferth T., Verdorfer I., Miyachi H., Sauerbrey A., Drexler H.G.,
RA   Chitambar C.R., Haber M., Gebhart E.;
RT   "Genomic imbalances in drug-resistant T-cell acute lymphoblastic CEM
RT   leukemia cell lines.";
RL   Blood Cells Mol. Dis. 29:1-13(2002).
//